Vivos Therapeutics, Inc. ( (VVOS) ) has released its Q1 earnings. Here is a breakdown of the information Vivos Therapeutics, Inc. presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Vivos Therapeutics, Inc. is a medical technology company specializing in innovative treatments for sleep-related breathing disorders, particularly obstructive sleep apnea (OSA), with FDA-cleared devices for both adults and children. In its latest earnings report, Vivos Therapeutics highlighted a strategic shift in its business model, focusing on direct sales and acquisitions, such as the pending acquisition of The Sleep Center of Nevada. The company’s first-quarter 2025 financial results showed a decline in total revenue to $3.0 million from $3.4 million in the previous year, attributed to a strategic pivot away from legacy service revenue. Despite this, product revenue increased by 8%, and operating expenses decreased by 5% year-over-year. Vivos reported a net loss of $3.9 million, slightly higher than the previous year’s $3.8 million. The acquisition of The Sleep Center of Nevada is expected to enhance Vivos’ market presence by providing access to a large patient base for its OSA treatments. Looking ahead, Vivos’ management remains optimistic about its growth prospects, emphasizing the potential of strategic alliances and acquisitions to expand its reach and diversify revenue streams.